截至1月26日收盘，猴痘概念上涨3.13%，位居概念板块涨幅第8，板块内，50股上涨，凯普生物、迈克 生物、之江生物等20%涨停，达安基因、科华生物等涨停，万孚生物、智飞生物、百普赛斯等涨幅居 前，分别上涨16.23%、14.87%、12.58%。跌幅居前的有谱尼测试、富祥药业、合富中国等，分别下跌 9.72%、5.51%、5.32%。 资金面上看，今日猴痘概念板块获主力资金净流入15.26亿元，其中，46股获主力资金净流入，6股主力 资金净流入超亿元，净流入资金居首的是智飞生物，今日主力资金净流入2.61亿元，净流入资金居前的 还有众生药业、君实生物、达安基因等，主力资金分别净流入2.23亿元、1.69亿元、1.65亿元。 今日涨跌幅居前的概念板块 | 688575 | 亚辉龙 | 1.73 | 2.31 | 1476.63 | 7.35 | | --- | --- | --- | --- | --- | --- | | 300439 | 美康生 | 5.17 | 7.59 | 1457.59 | 6.07 | | | 物 | | | | | | 300482 | 万孚生 | 16.23 | 15.99 | ...

| 601899 | 紫金矿 业 | 5.75 | 2.62 | 38.08 | 39.72 | 4.32 | | --- | --- | --- | --- | --- | --- | --- | | 300774 | 倍杰特 | 5.93 | 9.75 | 26.77 | 27.85 | 4.03 | | 000821 | ST京机 | 5.02 | 7.93 | 12.71 | 13.19 | 3.78 | （文章来源：证券时报网） | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 五日均线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 301080 | 百普赛 斯 | 14.92 | 5.22 | 63.72 | 70.79 | 11.09 | | 300871 | 回盛生 物 | 20.01 | 18.71 | 29.55 | 32.62 | 10.40 | | 300806 | 斯迪克 | 14.84 | 13.45 | 38.14 | ...

英国《独立报》23日称，印度当局正采取措施应对西孟加拉邦暴发的尼帕病毒疫情。当地媒体称，感染 者在加尔各答及周边地区医院接受治疗，其中一名病患病情危重，已有近百人被要求居家隔离。泰国民 航局宣布，26日起对来自印度西孟加拉邦的航班进行全面筛查，以防止尼帕病毒输入泰国。 1月26日，A股市场生物医药股全线上涨，其中，康乐卫士涨超20%，迈克生物、凯普生物、之江生 物、华兰疫苗20CM涨停，金迪克、智飞生物涨超13%，康希诺、百普赛斯涨超12%，东方生物涨超 11%，沃森生物、圣湘生物涨超10%，达安基因、科华生物10CM涨停，康泰生物、泓博医药涨超7%。 消息面上，近日，印度西孟加拉邦暴发尼帕病毒疫情，可人传人，死亡率最高达75%，尚无疫苗。 1998年到1999年，尼帕病毒导致的疫情曾在马来西亚、新加坡蔓延，导致百余人死亡，百万只猪因此被 扑杀，此后该疫情也曾在印度、孟加拉国、菲律宾暴发。世界卫生组织将尼帕病毒列为一种致命的人畜 共患病毒，主要由果蝠携带。该病毒可通过被污染的食物传播给人类，或直接人传人，死亡率在40%到 75%之间。据世卫组织介绍，这种病毒从感染到出现症状的潜伏期一般为4天至14天，最长可达 ...

1998年到1999年，尼帕病毒导致的疫情曾在马来西亚、新加坡蔓延，导致百余人死亡，百万只猪因此被 扑杀，此后该疫情也曾在印度、孟加拉国、菲律宾暴发。世界卫生组织将尼帕病毒列为一种致命的人畜 共患病毒，主要由果蝠携带。该病毒可通过被污染的食物传播给人类，或直接人传人，死亡率在40%到 75%之间。据世卫组织介绍，这种病毒从感染到出现症状的潜伏期一般为4天至14天，最长可达45天。 目前尚无专门针对尼帕病毒的疫苗和有效疗法。 | 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 920575 | 康乐卫士 | 海 | 20.48 | 33.71亿 | 45.10 | | 300463 | 迈克生物 | 1 | 20.03 | 85.86 Z | 26.90 | | 300639 | 凯普生物 | | 20.03 | 46.87 乙 | 34.76 | | 688317 | 之江生物 | 1 | 20.01 | 49.10亿 | 26.67 | | 301207 | 甲六段 | 1 | 20.00 | 140亿 ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 ACROBIOSYSTEMS CO., LTD 北京百普賽斯生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 重要提示 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代 表 閣下知悉、接納並向本公司、其獨家保薦人、整體協調人、顧問及包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據呈交香港公司註冊處註冊的本 公司文件作出投資決定；其副本將於發售期內向公眾人士派發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據本文 件中的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其任何補充、修訂或更換附頁，並不引起本公 ...

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]

Investment Rating - The report maintains an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The annual J.P. Morgan Healthcare Conference concluded successfully, with positive information from global pharmaceutical companies, including new pipeline disclosures and major deals. The report highlights the high prosperity in the innovative drug sector and recommends continuous investment in innovative drugs and the industry chain [25][26]. - The A-Shares pharmaceutical sector underperformed the market in the third week of January 2026, with the Shanghai Composite Index falling by 0.4% and the SW Pharmaceutical and Biological sector declining by 0.7% [8][27]. - The Hong Kong stock pharmaceutical sector performed in line with the market, while the U.S. pharmaceutical sector underperformed. The Hang Seng Healthcare index increased by 2.4%, and the S&P 500 Healthcare Select Sector decreased by 1.1% [28]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the high prosperity of innovative drugs and maintains overweight ratings for key pharmaceutical companies. It also recommends Biopharma/Biotech companies with promising pipelines and volume increases, as well as CXO and upstream companies benefiting from innovation [6][25]. Section 2: A-Shares Pharmaceutical Sector Performance - In the third week of January 2026, the A-Shares pharmaceutical sector's performance was ranked 17th among Shenwan primary industries, with a decline of 0.7%. The medical service sub-sector showed a positive performance of +3.3% [8][12][27]. Section 3: Hong Kong and U.S. Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector performed similarly to the market, while the U.S. sector underperformed. Notable gainers in the U.S. included MODERNA (+22%) and QUEST DIAGNOSTICS (+9%), while major decliners included BIOGEN (-12%) and BOSTON SCIENTIFIC (-10%) [28].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].

Group 1 - The core viewpoint of the news highlights the performance of the TaiKang Medical Health Fund, which saw declines in its two share classes, with Class C down by 13.45% and Class A down by 13.02% in 2025 [2][3] - The top ten holdings of the TaiKang Medical Health Fund in the third quarter of 2025 included companies such as JingTai Holdings, Kanglong Chemical, Fangzhou Jianke, SanSheng Pharmaceutical, Zhaoyan New Drug, Jiuan Medical, Yirui Technology, Lingrui Pharmaceutical, Baipusais, and Bid Medical [2] - The fund manager, Fu Hongzhe, has a background as a senior researcher at China Europe Fund Management Co., and has been with TaiKang since July 2019, becoming the fund manager on March 8, 2022 [2]

Core Viewpoint - The company Baipusais has shown a mixed performance in terms of stock trading and financial results, with a notable increase in revenue and net profit year-on-year, while also experiencing a decrease in shareholder numbers. Group 1: Stock Performance - On January 12, Baipusais' stock price fell by 0.39%, with a trading volume of 104 million yuan [1] - The financing buy-in amount for Baipusais on the same day was 7.01 million yuan, while the financing repayment was 6.58 million yuan, resulting in a net financing buy-in of 434,100 yuan [1] - As of January 12, the total balance of margin trading for Baipusais was 85.90 million yuan, which is 0.87% of its market capitalization and below the 40th percentile level over the past year, indicating a low financing balance [1] Group 2: Financial Performance - For the period from January to September 2025, Baipusais achieved an operating income of 613 million yuan, representing a year-on-year growth of 32.26% [2] - The net profit attributable to the parent company for the same period was 132 million yuan, reflecting a year-on-year increase of 58.61% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of Baipusais shareholders was 10,600, a decrease of 9.75% compared to the previous period [2] - The average number of circulating shares per shareholder increased by 54.93% to 11,947 shares [2] - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan distributed over the past three years [3]